相关实验视频

Updated: Jan 11, 2026

Murine Model of Intestinal Ischemia-reperfusion Injury

Murine Model of Intestinal Ischemia-reperfusion Injury

Published on: May 11, 2016

一种新型的Notch1-DLL4抑制剂减轻了肠道缺血-再输液损伤

Megan Tenet¹, Hui Jin², Saoirse Holland²

¹Center for Immunology and Inflammation, The Feinstein Institutes for Medical Research, Manhasset, NY; Department of Surgery, Zucker School of Medicine, Manhasset, NY.

|November 11, 2025

概括

一种新型的Notch1-delta类联结体4抑制显著降低了肠道缺血-再输液损伤的小鼠的炎症和器官损伤. 这种治疗性提高了生存率,显示出治疗相关疾病的前景.

科学领域:

生物医学研究的研究.
炎症和免疫学炎症和免疫学
血管生物学血管生物学

背景情况:

肠道缺血-再输液 (I/R) 损伤导致全身炎症和急性肺损伤 (ALI).
诺奇1信号通路由delta样联体4 (DLL4) 激活,在I/R损伤中加剧炎症.
开发了一种针对Notch1-DLL4相互作用的新抑制剂,以减轻这些影响.

研究的目的:

在肠道缺血-再输液 (I/R) 损伤的小鼠模型中研究Notch1衍生型抑制剂的三角形状联体4 (DLL4) 的治疗潜力.
确定这种抑制剂是否减轻全身炎症和急性肺损伤,从而改善结果.

主要方法:

雄性C57BL/6小鼠经历了60分钟的上半导体动脉封闭,以诱导肠道缺血症.
在再注血后,小鼠立即接受了静脉注射的Notch1-delta样联体4抑制剂或混杂.
对血和组织样本进行了炎症标志物,损伤标志物和组织学变化的分析;生存率被监测了36小时.

主要成果:

在I/R后的肺内皮细胞上,Notch1受体表达增加.
治疗Notch1-delta类联结物4抑制剂显著降低了IL-6,ALT,AST和LDH的血水平.
抑制剂降低了肠道和肺部的炎症基因表达,降低了肺损伤得分,并将生存率从13%提高到60%.

结论:

诺奇1-delta类联结体4抑制剂有效减轻炎症,并减少I/R后的肠道和肺部损伤.
这种治疗性可以降低炎症性细胞因子水平,减少细胞死亡,提高整体存活率.
诺奇1-delta类联结体4抑制剂是缓解与肠道缺血-再输液相关的损伤的有希望的治疗候选者.

更多相关视频

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

Visualization of Neutrophil Extracellular Traps in Mesenteric Venules After Mesenteric Ischemia-Reperfusion Injury via Intravital Microscopy

Visualization of Neutrophil Extracellular Traps in Mesenteric Venules After Mesenteric Ischemia-Reperfusion Injury via Intravital Microscopy

Published on: September 27, 2024

相关概念视频

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...

Notch Signaling Pathway

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...